Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. - Wikidata - awgldk - TriplyDB

Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.

Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q50907669

about

Cardiotoxicity in childhood cancer survivors: strategies for prevention and management Dexrazoxane does not protect against doxorubicin-induced damage in young rats Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography.Cardiac damage after treatment of childhood cancer: a long-term follow-up.The management of high-risk lymphoblastic leukaemia in children.Cardiovascular disease in adult survivors of childhood cancer.Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.Combination of dexamethasone, high-dose cytarabine, and carboplatin is effective for advanced large-cell non-Hodgkin lymphoma of childhood.Fetal cardiac effects of doxorubicin therapy for carcinoma of the breast during pregnancy: case report and review of the literature.Anthracycline cardiotoxicity: from bench to bedside.Cardiac function in long-term survivors of childhood lymphoma.Cardiovascular effects in childhood cancer survivors treated with anthracyclines.Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.Review of cardiotoxicity in pediatric cancer patients: during and after therapy.Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes Cardiovascular late effects.Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy.Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity Cardiac functional evaluation using vector velocity imaging after chemotherapy including anthracyclines in children with cancer.Endocrinological and cardiological late effects among survivors of childhood acute lymphoblastic leukemia.Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: a 5-year review at a single pediatric oncology center.An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies.Identifying cancer patients at risk for cardiotoxicity.Prevention of cardiotoxicity among survivors of childhood cancer.Late Cardiotoxicity: Issues for Childhood Cancer Survivors.Caring for cancer survivors: more than just checking the blood pressure and measuring the ejection fraction.Chemotherapy-induced cardiotoxicity in children.Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study.Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the L.E.A. program.Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.

P2860

Q24628695-9C81C945-ED44-4879-8B7D-8DB67D843363 Q28572861-B05F66CC-DD86-44CA-BA1A-94835D695265 Q30491590-E9AE53F2-FE91-44D0-B487-9F2035FD4490 Q33336217-D5651AB9-1059-48C9-96F2-9E968823D28E Q33848509-AA7B00D2-58DA-4C85-8A59-FCD1021FACA2 Q34042984-F2E572E6-76BE-45FF-A091-AB14666155A5 Q34073681-C84B0708-BB93-4F72-A0EF-1A60CC968F2E Q34287195-1E2BF2DA-8F45-45B9-AAD1-11A01C274519 Q34328387-1DC91151-8D54-48DE-BFD1-93DAAAFA1C16 Q34477415-5BB0EC99-3692-41C3-90B0-F82E7F6BA10F Q34557579-8BC282E4-6271-4390-B2D7-AC6B6FC1B854 Q34572109-09AB8F9D-E1B0-4F93-A935-0EEB9E24CD05 Q34746933-8AB6E47F-AF23-4A10-B9D7-9155143E0569 Q35008126-AF512887-279F-446E-931E-7D86EC7FF120 Q35616085-FCFCB671-8834-4B9E-B9C5-15BBD2ADC052 Q35757419-BB88CED3-3AE8-498B-94AA-2DBEA30CDABC Q35888110-F582E428-1400-4A77-8EF6-14542A453F66 Q35925266-B937494D-A0F7-477C-B067-A2D2271253F0 Q35969396-9DE673C0-5903-4159-9D23-7D07CB1187CD Q36425761-CD046D1C-CEB4-428F-BDED-3D7FCAE30CB3 Q36625957-49DA4D9F-6F60-4F03-B12D-141BF9250C21 Q36649653-D3EC5CB9-E7A5-4E1D-BFE0-FF4A1DBEF4FD Q36828128-4EE9A2E5-A3D1-4747-A69A-A4DDD48E74C2 Q37038711-04521232-06B5-4C45-BB15-5FDE9202634C Q37059586-E5D612B7-2B6A-4BB9-BC75-4FBC29DD3C76 Q37129069-B345CBE1-492C-42EE-8D03-A54756238231 Q37230118-D9EBA5A4-04FB-42DE-9CEF-EAE881521F1B Q37408759-69AD2C59-1DBE-4F88-BEC9-FFA9346F15EE Q37426570-F143E822-F318-463E-A345-6A0025D2EE1E Q37924696-72A06F52-3679-40E5-97C8-6B26E7CD4CFF Q38109236-60446F00-534E-44C1-912D-793D5F9EF4FA Q38551772-1E25868D-B421-4F50-B374-3C83CECA785E Q38824644-DE63B52D-01C9-471C-B9F6-8DAEE97B503C Q38845457-CEDB4E3E-D895-4BD5-8A53-8D7C261DF32B Q38978062-7FBC3467-259C-4736-BFDC-91238C4E99FB Q39415815-30F61C5B-CDAB-48A4-A293-64C3D5C89671 Q40325703-89AB9C00-EDE6-4C31-A341-DAAB0F687BF2 Q42573851-C5AA0083-F26B-4A75-99B9-A106412744C8 Q43683849-4151A5ED-100F-4656-AAD0-DA9844A7A43B Q45073135-F16652E9-580E-4762-9C75-586A3BED536B

P2860

Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q50907669

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年学术文章

@wuu

1998年学术文章

@zh

1998年学术文章

@zh-cn

1998年学术文章

@zh-hans

1998年学术文章

@zh-my

1998年学术文章

@zh-sg

1998年學術文章

@yue

1998年學術文章

@zh-hant

name

Relationship between cumulativ ...... acute lymphoblastic leukemia.

@en

Relationship between cumulativ ...... acute lymphoblastic leukemia.

@nl

type

label

Relationship between cumulativ ...... acute lymphoblastic leukemia.

@en

Relationship between cumulativ ...... acute lymphoblastic leukemia.

@nl

prefLabel

Relationship between cumulativ ...... acute lymphoblastic leukemia.

@en

Relationship between cumulativ ...... acute lymphoblastic leukemia.

@nl

P1433

Q50907669-6B5F9286-026F-4AF1-AB51-735067203EE3

P1476

Q50907669-542AC837-4F80-4047-B222-9B5A84D1C6E0

P2093

Q50907669-0D88A402-77D3-433D-86D3-664112C799AA

Q50907669-0E04B973-68C5-4C08-B513-AEC5A04B89D2

Q50907669-2251E71E-7865-4C2D-83AA-2ADAE8629909

Q50907669-50554C19-8CF4-4C23-AC55-FEA464743B23

Q50907669-5079EBF3-22FF-47A6-8BBC-EAF220929CB7

Q50907669-7ECAD365-07C1-48A0-9545-E467F9179224

Q50907669-80BF0947-928C-4468-8536-AFCAA2AC682F

Q50907669-8DD5E9DD-5BF4-4CA8-92F2-33EFABB0ADE7

Q50907669-A32ED0B3-4381-4B25-9D32-6039E1C6C0BF

Q50907669-F32FB8EE-EE07-4540-9C55-24079B27122D

P304

Q50907669-8E98B141-4600-494A-B7BD-76B4D2F21376

P31

Q50907669-5979C471-ACEC-47C5-B908-0A1D90642688

P356

Q50907669-BED93FAC-8CCC-4BF1-A5E3-AB58C8CE1767

P407

Q50907669-E5B83854-1831-48FF-A349-5386222EDB0E

P433

Q50907669-0F0B13F2-3427-4AAA-B3A9-2662960CAA3D

P478

Q50907669-10B19D08-991F-4ACE-AE40-A85C315A67F5

P50

Q50907669-5593A04B-8797-4956-B717-3111AEF647DB

P577

Q50907669-6A545C1E-8628-4861-8BF1-7DFD82DAD549

P698

Q50907669-2BC6C4A1-CEE8-4405-8160-98D758405D41

P921

Q50907669-E3739495-CD7E-4404-A615-D5972D4D1F27

P356

JCO.1998.16.2.545

P1433

Journal of Clinical Oncology

P1476

Relationship between cumulativ ...... acute lymphoblastic leukemia.

@en

P2093

E J Orav

http://www.w3.org/2001/XMLSchema#string

H Hertz

http://www.w3.org/2001/XMLSchema#string

J R Jacobsen

http://www.w3.org/2001/XMLSchema#string

K Holm

http://www.w3.org/2001/XMLSchema#string

K Nysom

http://www.w3.org/2001/XMLSchema#string

S D Colan

http://www.w3.org/2001/XMLSchema#string

S E Lipshultz

http://www.w3.org/2001/XMLSchema#string

S E Sallan

http://www.w3.org/2001/XMLSchema#string

S M Mone

http://www.w3.org/2001/XMLSchema#string

S R Lipsitz

http://www.w3.org/2001/XMLSchema#string

P304

545-550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.1998.16.2.545

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Jørgen H Olsen

P577

1998-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9469339

http://www.w3.org/2001/XMLSchema#string

P921